Particularly in prostate cancer, one of the major hurdles is the existence of negative feedback between AKT and AR signaling pathways, making a single blockage of AKT signaling inefficient in the treatment of prostate cancer. The gene discussed is AKT1; the disease is Familial prostate cancer.